2025 연구자 정보 (24 / 654)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Hur, Moon Haeng (Hur, MH) |
Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea Seoul Natl Univ, Liver Res Inst, Coll Med, Seoul, South Korea |
|
0000-0001-5463-6782 Hur, Moon Haeng |
[JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com | ||
|
Jang, Heejoon (Jang, H) |
Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Seoul, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Daegu, South Korea |
|
|
[JCR상위 1.7%] Long-term clinical outcomes across biopsy-confirmed steatotic liver disease categories: a multicenter prospective cohort study using merged data | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | wonshiri@yahoo.com | ||
|
Jeong, Jae Yoon (Jeong, JY) |
Ewha Womans Univ, Seoul, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Daegu, South Korea |
|
|
[JCR상위 1.7%] Long-term clinical outcomes across biopsy-confirmed steatotic liver disease categories: a multicenter prospective cohort study using merged data | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | wonshiri@yahoo.com | ||
|
Jeong, Seol-Hwa (Jeong, SH) |
|
|
[JCR상위 1.7%] Role of EMP2 in triple-negative breast cancer. | SCIE | 1.7 | ONCOLOGY | ||||
|
Jia, Jidong (Jia, JD) |
제1저자 | Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China |
|
|
[JCR상위 1.7%] Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | jia_jd@ccmu.edu.cn | |
|
Jiang, Zefei (Jiang, ZF) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Kang, Jieun (Kang, J) |
|
|
[JCR상위 1.7%] Role of EMP2 in triple-negative breast cancer. | SCIE | 1.7 | ONCOLOGY | ||||
|
Kang, Seok Yun (Kang, SY) |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY | ||||
|
Kann, Ariel Galapo (Kann, AG) |
|
|
[JCR상위 1.7%] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Kemal, Yasemin (Kemal, Y) |
|
|
[JCR상위 1.7%] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Kim, Eun Ae (Kim, EA) |
|
|
[JCR상위 1.7%] Role of EMP2 in triple-negative breast cancer. | SCIE | 1.7 | ONCOLOGY | ||||
|
Kim, Gi-Ae (Kim, GA) |
Kyung Hee Univ Hosp, Seoul, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Daegu, South Korea Kyung Hee Univ, Kyung Hee Univ Hosp, Coll Med, Dept Internal Med,Div Gastroenterol, Seoul, South Korea Kyung Hee Univ, Kyung Hee Univ Hosp, Coll Med, Div Hepatol,Dept Internal Med, Seoul, South Korea Kyung Hee Univ, Kyung Hee Univ Hosp, Seoul, South Korea |
AAZ-2547-2021 Kim, Gi-Ae |
|
[JCR상위 1.7%] Long-term clinical outcomes across biopsy-confirmed steatotic liver disease categories: a multicenter prospective cohort study using merged data [JCR상위 1.7%] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B [JCR상위 1.0%] Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial |
SCIE | 1.0 | GASTROENTEROLOGY & HEPATOLOGY |
wonshiri@yahoo.com pindra@empal.com limys@amc.seoul.kr |
||
|
Kim, Gun Min (Kim, GM) |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY | ||||
|
Kim, Han Jo (Kim, HJ) |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY | ||||
|
Kim, Hee Jun (Kim, HJ) |
|
|
[JCR상위 1.7%] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY |
페이지 이동: